Tamara Kokaz

Tamara Kokaz has extensive experience in the field of pharmacovigilance and medical affairs. Tamara is the current Medical Affairs Director at Pleco Therapeutics BV, a position they have held since January 2023. Prior to this, Tamara worked at Consilient Health as the Head of Pharmacovigilance & Medical Information from May 2021 to December 2022. Before that, they were a Pharmacovigilance Partnering Specialist at Roche from August 2020 to May 2021, and a Pharmacovigilance Audit Manager at Norgine from March 2020 to August 2020.

Tamara's earlier roles include Pharmacovigilance Manager at Clinigen Group from July 2016 to March 2020. Tamara also served as a Drug Safety Specialist and Drug Safety and Medical Affairs Officer at Clinigen Group from May 2016 to July 2016 and from April 2015 to May 2016, respectively. Prior to their tenure at Clinigen Group, they worked as a Drug Safety Associate at Johnson & Johnson from 2014 to 2015.

Tamara's career in pharmacovigilance started at the Medicines and Healthcare Products Regulatory Agency (MHRA) where they worked as a Pharmacovigilance Service Team Officer from May 2013 to May 2014. Tamara began their professional journey as a Pharmacovigilance Officer at PharSafer from May 2011 to December 2011.

Tamara Kokaz obtained a Higher National Diploma in Biomedical Sciences from Kingston College between 2006 and 2008. Tamara then pursued a Bachelor of Science (BSc) in Pharmacology at Kingston University, completing their studies in 2011. In 2012, they obtained a Master of Science (MS) in Clinical Drug Development from Queen Mary University of London, specializing in Clinical and Industrial Drug Development.

In terms of additional certifications, Tamara obtained a certification in First Line Managers from ILM in June 2022. Tamara also became a Mental Health First Aider through Mental Health First Aid (MHFA) England in October 2021. Furthermore, they earned a certification in Advanced medical information skills from the Pharmaceutical Information and Pharmacovigilance Association (PIPA) in July 2021. It is worth noting that there is mention of an additional certification related to Orphan Drugs Clinical Trials, but there is no specific information provided regarding when or where this certification was obtained.